Pralsetinib

Pralsetinib is a targeted therapy medication belonging to the class of tyrosine kinase inhibitors (TKIs). It specifically targets and inhibits rearranged during transfection (RET) kinase activity, which plays a role in promoting cancer cell growth. Pralsetinib is used in the treatment of certain types of cancers that harbor RET gene alterations, such as non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC).

Indications

-Treatment of adult patients with advanced or metastatic RET fusion-positive NSCLC who have progressed on platinum-based chemotherapy and another RET inhibitor if previously treated. -Treatment of adult patients with advanced or metastatic RET-mutant MTC who require systemic therapy and have progressed on prior treatment.

Dosage

-The recommended dosage of pralsetinib is typically 400 mg orally once daily, with or without food. -Dosage adjustments may be necessary based on individual patient factors such as tolerability and response to treatment.

Contra-Indications

Hypersensitivity to pralsetinib or any component of the formulation.

Special Precautions

-Monitor for signs of interstitial lung disease (ILD) or pneumonitis; interrupt or discontinue treatment if these occur. -Assess thyroid function before starting pralsetinib and monitor regularly during treatment, as thyroid abnormalities may occur. -Use caution in patients with hepatic impairment; adjust dosage if necessary based on liver function tests.

Side Effects

Common side effects of pralsetinib may include: -Fatigue -Constipation -Muscle pain -Elevated liver enzymes -Hypertension

Drug Interactions

Pralsetinib may interact with medications metabolized by CYP3A enzymes or drugs that affect gastric pH. Avoid concomitant use with strong CYP3A inhibitors or inducers.